Oncology

Facing the biotech cash crunch, Context Therapeutics shelves one drug to double down on two others, a strategic pivot that secures its future into late 2027.

Acrivon's ACR-2316 shows durable responses in lung cancer, moving to the next phase. The trial's design, guided by AI, aligns with new FDA standards.

As Ascentage Pharma preps its mid-year report, we look beyond the balance sheet at the strategic plays and clinical trials fueling its global oncology ambitions.

ZAP Surgical's expansion in China is more than a business win. It signals a future where brain surgery is non-invasive, vault-free, and radically accessible.

With a fortified balance sheet and a strategic pivot, OnKure Therapeutics is betting that precision and selectivity will conquer a competitive drug market.

In a strategic play, Archeus Technologies overhauls its advisory board, positioning itself to accelerate its cancer therapy pipeline in the booming RPT market.

Saint Agatha Foundation's record grant, born from personal loss, is bringing advanced diagnostic and surgical technology to rural New York, tackling a critical gap.

After a corporate overhaul and a massive cash infusion, Faeth Therapeutics is pushing its multi-pronged cancer drug PIKTOR toward pivotal clinical data.

An award for a Virginia nurse is more than a headline. It's a signal of a strategic revolution in healthcare, where community clinics become global powerhouses.

A new strategic alliance aims to dismantle geographic barriers in oncology by decentralizing diagnostics, a move with profound implications for patient access.

IDEAYA Biosciences advances its breakthrough melanoma drug toward FDA review while its $1.24B cash runway fuels a deep pipeline targeting cancer's toughest codes.

LabPMM's new global KMT2A MRD test offers ultra-sensitive monitoring for aggressive leukemias, aiming to improve patient outcomes and streamline trials for menin inhibitors.

Pathos AI leverages its Foundry platform to ink a $2.2B deal with Alphamab for a novel cancer drug, signaling a new era of AI-led pharma strategy.

Gene Solutions’ academy in Malaysia signals a shift from complex genomic data to empowering clinicians with actionable insights for a new era of cancer care.

Tennessee Oncology's new Tullahoma center isn't just a building. It's a calculated move in the decentralization of advanced medicine, a model reshaping patient care and regional economies.

The Oncology Institute's transformation into Starling Oncology signals a strategic pivot to solve the cancer cost crisis through a tech-enabled, coordinated model.

Karyopharm plans an accelerated FDA filing for its selinexor combo in myelofibrosis. The move hinges on a key surrogate endpoint and a race against competitors.

Karyopharm's stock plummets after a key cancer trial fails, forcing a strategic retreat and a hard pivot toward more promising assets in its pipeline.

Dr. Howard Bailey, a top cancer center leader, joins Cofactor Genomics. It's a strategic bet on RNA's power to finally predict immunotherapy success.